FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma

Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population.05/21/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news